Mölnlycke’s science-based targets validated
The Science Based Targets initiative (SBTi) has validated that the greenhouse gas (GHG) emission reduction targets submitted by Mölnlycke Health Care conform to the SBTi criteria and recommendations and are aligned with the 1.5°C trajectory. This is the next step towards Mölnlycke’s ambition to help decarbonise healthcare.

Today, Mölnlycke Health Care, a world leading MedTech company, announces that its near-term GHG emission reduction targets submitted to the SBTi have been validated and deemed to be compliant with all applicable requirements.
Specifically, Mölnlycke has committed to reduce absolute scope 1 and 2 GHG emissions by 50% by 2030, from a 2021 base year, to increase active annual sourcing of renewable electricity from 23% in 2021 to 100% by 2024, and to continue sourcing of 100% renewable electricity through 2030.
Furthermore, the company committed to reducing absolute scope 3 GHG emissions from purchased goods and services, fuel and energy related activities, upstream transportation and distribution and waste generated in operations by 20% by 2028, from a 2021 base year.
Finally, Mölnlycke committed that 63% of its suppliers by emissions covering purchased goods and services, capital goods, and upstream transportation and distribution, will have set science-based targets by 2028.
“SBTi validation is a key milestone in our long-term strategy to help decarbonise the healthcare sector” said Zlatko Rihter, Chief Executive Officer, Mölnlycke Health Care. “We are committed to reach Net Zero by 2050 at the latest, and are accelerating the process of minimising both the direct and indirect impact of our operations on the planet.”
Mölnlycke stands well poised for reaching the targets through a series of impact initiatives:
- For scope 1 and scope 2 targets concerning our own manufacturing facilities and headquarters, Mölnlycke’s implementation of a renewable electricity roadmap is well underway and will be achieved through a combination of virtual Power Purchase Agreements, renewable energy certificates (RECs) and investments in higher additionality energy sources, e.g. photovoltaic systems.
- For scope 3 and the supplier engagement target, Mölnlycke has already initiated activities under the Sustainable Procurement framework aimed at increasing collaboration with suppliers to bring innovation in raw materials and improved transportation routes that are needed to transition to a low-carbon economy. Mölnlycke are ensuring a defined set of suppliers commit to reducing emissions through the SBTi.
The official information on Mölnlycke’s commitment can be found here.
About SBTi
The Science Based Targets Initiative (SBTi) is a global partnership made up of leading climate organisations, including the Carbon Disclosure Project, the United Nations Global Compact, World Resources Institute (WRI) and the World Wide Fund for Nature (WWF). The SBTi defines and promotes best practice in emissions reductions and Net-zero targets in line with science. It provides technical assistance and expert resources to companies that set science-based targets, to ensure their alignment with the Paris Agreement, to limit global warming to 1.5C.
Latest press releases
Go to Media room-
Mölnlycke Health Care publishes Annual report for 2024
Gothenburg, Sweden. 1 April 2025. Today Mölnlycke Health Care has published its Annual report for 2024, including the sustainability report.
-
New study demonstrates the potential benefits of dressing regime improvements in delivering value-based chronic wound care
-
Mölnlycke Health Care announces launch of the 2025 Future Summit
Mölnlycke Health Care’s Wound Care business area is delighted to announce the launch of its 2025 Future Summit, an educational event bringing together healthcare professionals (HCPs) from across Europe, the Middle East, and Africa (EMEA).
-
Mölnlycke Health Care reaches 100% renewable electricity target
Mölnlycke, a world leading MedTech company, has secured 100% renewable electricity for all its established and new manufacturing sites and its headquarters, reaching its first near-term SBTi (Science Based Targets initiative)-validated target.
-
Mölnlycke Health Care announces USD 8 million investment in diabetic foot ulcer management system company Siren
-
Mölnlycke Health Care wins Swedish Sustainability Tech award
Mölnlycke is proud to announce that it has been awarded the Capgemini Swedish Sustainability Tech Award 2024 for Mölnlycke ProcedurePak® trays. This accolade recognises the company’s innovative practices and dedication to revolutionise healthcare for people and planet.
-
Mölnlycke Health Care appoints Guillaume Joucla as Chief Financial Officer
Joucla’s extensive experience and insights to drive financial strategy and growth initiatives.
-
Mölnlycke Health Care and Operation Smile help to change people's lives with newly inaugurated cleft care centre in Philippines
The centre is expected to serve 10,000 patients in the region with transformative cleft care in the first three years of operations.
-
Mölnlycke® Health Care and Transdiagen announce research collaboration to drive innovation in wound care